# Junta clínica — PT-pseudo_5af00f9153c2 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_5af00f9153c2",
  "pid": "PT-pseudo_5af00f9153c2",
  "task": 1,
  "psa": 11.2,
  "age": 64,
  "months": 2,
  "pirads": "5",
  "psad": 0.18,
  "psav": 1.9,
  "psap": 7.5,
  "vol": 61.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8541575,
  "medhx": "Type 2 diabetes, Hypercholesterolaemia, Chronic kidney disease",
  "meds": "metformin, empagliflozin, atorvastatin, simvastatin, rosuvastatin",
  "notes": "PSA 11.2 ng/mL. PI-RADS 5. PSAD 0.18. Prostate volume 61 mL. csPCa 0.85.",
  "pmhx": [
    "Type 2 diabetes",
    "Hypercholesterolaemia",
    "Chronic kidney disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "95 kg",
    "height": "173 cm",
    "bmi": "31.7",
    "bp": "99/73 mmHg",
    "hr": "81 bpm",
    "smoking": "Ex-smoker (29 pack-yr, quit 2001)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "31 Jan 2025",
  "enc_ref": "Dr. P. van Dijk (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Evaluation initiated after documenting a sustained PSA elevation alongside a previous biopsy result establishing ISUP grade group 4 malignancy."
    },
    {
      "s": "History",
      "t": "A 64-year-old factory supervisor, currently cohabiting with his partner after a divorce, seeks re-assessment of a known prostate malignancy. His PSA values have climbed steadily from 3.3 ng/mL in early 2023 to the present 11.2 ng/mL. Underlying type 2 diabetes and chronic kidney disease are managed with metformin and empagliflozin, while hypercholesterolaemia is addressed through a combination of atorvastatin, simvastatin, and rosuvastatin. His estimated glomerular filtration rate has held steady beneath 60 mL/min/1.73m2. Urological discomfort is negligible, reflected by an IPSS score of 4, and he denies any blood in the urine or voiding difficulties. A significant smoking background of 29 pack-years ended in 2001; alcohol consumption remains limited to four units per week. He favors weekend gardening over formal exercise routines. Recent non-urological care included a standard chest radiograph and an audiology check for mild age-related hearing shifts, alongside a persistent sleep disturbance he links to occupational stress. Due to residing over ninety minutes from the clinic, he has asked that telephone consultations be utilized whenever medically suitable."
    },
    {
      "s": "Physical examination",
      "t": "Digital rectal assessment: Normal DRE — prostate measures approximately 60 g with a smooth, firm consistency and no detectable nodules or asymmetry.\nSystemic evaluation shows no abnormalities. Vital parameters remain stable at a blood pressure of 99/73 mmHg and a heart rate of 81 bpm. Body mass index registers at 31.7, aligning with his reported activity levels. Peripheral lymph nodes are non-palpable, and suprapubic regions exhibit no tenderness."
    }
  ],
  "occupation": "factory supervisor",
  "marital": "Divorced",
  "living": "Lives with partner",
  "next_of_kin": "Sibling (brother)",
  "recent_other": [
    "Audiology — hearing test",
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "4 units / week",
  "exercise": "Gardening, no structured exercise",
  "ipss": "IPSS score: 4/35 (mild LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_5af00f9153c2
Task: 1

Encounter: Urology - outpatient on 31 Jan 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 64-year-old male
  - PSA: 11.2 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.18 ng/mL²
  - PSA velocity: 1.9 ng/mL/yr
  - Prior PSA: 7.5 ng/mL
  - Prostate volume: 61.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8541575 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Hypercholesterolaemia, Chronic kidney disease
  - Problem list / PMHx: Type 2 diabetes, Hypercholesterolaemia, Chronic kidney disease
  - Current medication: metformin, empagliflozin, atorvastatin, simvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 11.2 ng/mL. PI-RADS 5. PSAD 0.18. Prostate volume 61 mL. csPCa 0.85.

Vitals: weight 95 kg, height 173 cm, BMI 31.7, BP 99/73 mmHg, HR 81 bpm. Smoking: Ex-smoker (29 pack-yr, quit 2001).

Chief complaint: Evaluation initiated after documenting a sustained PSA elevation alongside a previous biopsy result establishing ISUP grade group 4 malignancy.

History: A 64-year-old factory supervisor, currently cohabiting with his partner after a divorce, seeks re-assessment of a known prostate malignancy. His PSA values have climbed steadily from 3.3 ng/mL in early 2023 to the present 11.2 ng/mL. Underlying type 2 diabetes and chronic kidney disease are managed with metformin and empagliflozin, while hypercholesterolaemia is addressed through a combination of atorvastatin, simvastatin, and rosuvastatin. His estimated glomerular filtration rate has held steady beneath 60 mL/min/1.73m2. Urological discomfort is negligible, reflected by an IPSS score of 4, and he denies any blood in the urine or voiding difficulties. A significant smoking background of 29 pack-years ended in 2001; alcohol consumption remains limited to four units per week. He favors weekend gardening over formal exercise routines. Recent non-urological care included a standard chest radiograph and an audiology check for mild age-related hearing shifts, alongside a persistent sleep disturbance he links to occupational stress. Due to residing over ninety minutes from the clinic, he has asked that telephone consultations be utilized whenever medically suitable.

Physical examination: Digital rectal assessment: Normal DRE — prostate measures approximately 60 g with a smooth, firm consistency and no detectable nodules or asymmetry.
Systemic evaluation shows no abnormalities. Vital parameters remain stable at a blood pressure of 99/73 mmHg and a heart rate of 81 bpm. Body mass index registers at 31.7, aligning with his reported activity levels. Peripheral lymph nodes are non-palpable, and suprapubic regions exhibit no tenderness.

Patient info: factory supervisor; Divorced; Lives with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 4 units / week; exercise Gardening, no structured exercise; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Radiology — chest X-ray (routine).
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.58
  uncertainty  +/- 0.11 epistemic (95% band 0.36-0.80); among patients I cannot tell apart the outcome was 0.98 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.74: PI-RADS 5, PSA 12.0, PSAD 0.28, age 61, DRE Normal -> DEFER (borderline). He wrote: "Young patient with elevated PSA (>10), elevated PSA density, PIRADS5 and ISUP GG2 disease -> low threshold for recommending curative treatment. IF patient does not want…"
  2. distance 1.00: PI-RADS 5, PSA 19.0, PSAD 0.37, age 65, DRE Normal -> DEFER (clear). He wrote: "Patient needs treatment without repeat biopsy as earlier biopsy showed ISUP4"
  3. distance 1.16: PI-RADS 5, PSA 11.0, PSAD 0.108, age 70, DRE Normal -> BIOPSY (borderline). He wrote: "Patient on Activ Surveillance with severe LUTS symptoms. There are two options , recommend surgery direkt or do a new biopsy."

PRECEDENT: DEFER (weighted vote 0.27 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guideline discusses using a risk-adapted matrix table linking PI-RADS score and PSA density categories to guide the decision to perform a biopsy. It states that for patients with PI-RADS scores of 1-3 and a low-risk profile (PSA-D < 0.15ng/mL/cc, negative DRE, no family history, no ASAP or ISUP1 cancer at prior biopsy), biopsy could have been avoided in 99 men while missing ISUP GG 2 cancers in six men.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not settled by the guideline because the guideline emphasizes a risk-adapted matrix based on multiple variables, not just the presence of a prior positive biopsy. Expert 4's focus on the prior biopsy grade and surveillance history is not decisive because the guideline suggests that the decision depends on whether the patient fits a low-risk profile defined by multiple factors.

WHAT WE STILL NEED
The guideline requires the PSA density value to determine the risk category. The panel shows the PSA density is 0.18 ng/mL², which falls into the Intermediate-high category according to the retrieved table. The guideline requires the documented grade of the prior biopsy to be known to determine if the patient fits the low-risk profile.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the grade of the prior biopsy and the surveillance status documented in the previous notes to determine the appropriate next step.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the mpMRI?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend?
  previous_notes (get_previous_notes) -> What is the documented grade of the prior biopsy (Gleason or ISUP), the number and dates of biopsy sessions, and whether he is on a surveillance protocol with a confirmatory biopsy due?
  laboratory_results (get_lab_results) -> What are the full laboratory results, including free-PSA fraction, renal function, haemoglobin, and DRE filing?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy?
  Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion size and zone of the mpMRI is approx. "18 mm" in the "left peripheral zone (base/mid)".
psa_trend
The serial PSA value trend is: {"date": "Mar 2023", "val": 3.8}, {"date": "Sep 2023", "val": 5.0}, {"date": "Feb 2024", "val": 6.5}, {"date": "Aug 2024", "val": 8.5}, {"date": "Jan 2025", "val": 11.2}.
previous_notes
The documented grade of the prior biopsy is "not recorded", the number and dates of biopsy sessions is "not recorded", and whether he is on a surveillance protocol with a confirmatory biopsy due is "not recorded".
laboratory_results
The full laboratory results include: PSA "11.2 ng/mL" on "25 Dec 2024", Free PSA "2.15 ng/mL" on "25 Dec 2024", "%Free PSA" "19%" on "25 Dec 2024", Haemoglobin "15.4 g/dL" on "25 Dec 2024", WBC "5.1 x10^9/L" on "25 Dec 2024", Platelets "201 x10^9/L" on "25 Dec 2024", Creatinine "173 umol/L" on "25 Dec 2024", eGFR "<60 mL/min/1.73m2" on "25 Dec 2024", Testosterone "17.3 nmol/L" on "25 Dec 2024", Alkaline phosphatase "88 U/L" on "25 Dec 2024", LDH "216 U/L" on "25 Dec 2024".

WHAT I DID NOT OPEN
family-history anamnesis, because the information was not required to answer the open questions.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS score of "5" from the mpMRI report.
PSA density of "0.18 ng/mL/mL" which falls into the Intermediate-high category according to the EAU guideline.
PSA velocity of "1.9 ng/mL/yr" from the PSA trend.
Findings that argue AGAINST sampling this patient now:
The documented grade of the prior biopsy is "not recorded".
The patient is not explicitly stated to be on a surveillance protocol with a confirmatory biopsy due.

WHERE THIS LEANS
The documents confirm a high-risk imaging finding (PI-RADS 5) and an intermediate-high PSA density, but the critical information regarding the prior biopsy result and surveillance status remains missing.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 11.20 ng/mL over 5 points spanning 22 months; velocity +3.98 ng/mL per year; doubling time about 14 months.
PROJECTION at 6 months: 15.4 ng/mL, conformal 95% band 4.4-53.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.56
  uncertainty  +/- 0.09 epistemic (95% band 0.39-0.73), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.58  ('discuss' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.56  ('discuss' tier, fusion_full)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.27  (k=3 precedents)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.52 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar appear to address the moderator's questions, although the answers are incomplete. The `previous_notes` explicitly state that the documented grade of the prior biopsy, the number and dates of biopsy sessions, and surveillance status are "not recorded."

ALIGNMENT WITH THE PANEL
The panel protocol concluded with a weighted vote for BIOPSY (p=0.52), driven by Expert 1 and Expert 3, despite the lack of documented prior grade. The retrieved evidence supports the high-risk imaging (PI-RADS 5) and intermediate-high PSA density, which aligns with the factors weighted by the trace model.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy? This question remains unanswered, as the registrar reported this information was "not recorded."
Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due? This question also remains unanswered, as the registrar reported this was "not recorded."

WHAT CARRIES WEIGHT, AND WHY
The most relevant variables are the PI-RADS score of 5, the PSA density of 0.18 ng/mL², and the missing documentation of the prior biopsy grade and surveillance status. These matter because the EAU guideline requires the prior biopsy grade to determine if the patient fits a low-risk profile, which is the basis for avoiding biopsy.

MY SUGGESTION TO THE CHAIR
Given that the critical information required by the guideline—the prior biopsy grade—is missing, the decision cannot be definitively made based on the retrieved evidence alone. The panel's decision rests on the trained experts' weighted vote despite this gap.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Given the high-risk imaging finding of PI-RADS 5 and the intermediate-high PSA density of 0.18 ng/mL², coupled with a rising PSA trend of 1.9 ng/mL/yr, a biopsy is indicated to establish the true pathological grade. The decision is supported by the convergence of expert assessments, particularly the fusion classifier's suggestion, despite the lack of documented prior biopsy grading in the retrieved notes.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
